Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response
In the last decade, a plethora of immunotherapeutic strategies have been designed to modulate the tumor immune microenvironment. In particular, immune checkpoint (IC) blockade therapies present the most promising advances made in cancer treatment in recent years. In non-small cell lung cancer (NSCLC...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2243169 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846102249947791360 |
|---|---|
| author | Assia Hijazi Carlotta Antoniotti Chiara Cremolini Jérôme Galon |
| author_facet | Assia Hijazi Carlotta Antoniotti Chiara Cremolini Jérôme Galon |
| author_sort | Assia Hijazi |
| collection | DOAJ |
| description | In the last decade, a plethora of immunotherapeutic strategies have been designed to modulate the tumor immune microenvironment. In particular, immune checkpoint (IC) blockade therapies present the most promising advances made in cancer treatment in recent years. In non-small cell lung cancer (NSCLC), biomarkers predicting response to IC treatments are currently lacking. We have recently identified Immunoscore-IC, a powerful biomarker that predicts the efficiency of immune-checkpoint inhibitors (ICIs) in NSCLC patients. Immunoscore-IC is an in vitro diagnostic assay that quantifies densities of PD-L1+, CD8+ cells, and distances between CD8+ and PD-L1+ cells in the tumor microenvironment. Immunoscore-IC can classify responder vs non-responder NSCLC patients for ICIs therapy and is revealed as a promising predictive marker of response to anti-PD-1/PD-L1 immunotherapy in these patients. Immunoscore-IC has also shown a significant predictive value, superior to the currently used PD-L1 marker. In colorectal cancer (CRC), the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic CRC. In the AtezoTRIBE trial, Immunoscore-IC emerged as the first biomarker with robust predictive value in stratifying pMMR metastatic CRC patients who critically benefit from checkpoint inhibitors. Thus, Immunoscore-IC could be a universal biomarker to predict response to PD-1/PD-L1 checkpoint inhibitor immunotherapy across multiple cancer indications. Therefore, cancer patient stratification (by Immunoscore-IC), based on the presence of T lymphocytes and PD-L1 potentially provides support for clinicians to guide them through combination cancer treatment decisions. |
| format | Article |
| id | doaj-art-09f80004c60e4f23ae689021c50d6ce1 |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-09f80004c60e4f23ae689021c50d6ce12024-12-27T17:34:38ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2243169Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy responseAssia Hijazi0Carlotta Antoniotti1Chiara Cremolini2Jérôme Galon3INSERM, Laboratory of Integrative Cancer Immunology, Paris, FranceDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, ItalyINSERM, Laboratory of Integrative Cancer Immunology, Paris, FranceIn the last decade, a plethora of immunotherapeutic strategies have been designed to modulate the tumor immune microenvironment. In particular, immune checkpoint (IC) blockade therapies present the most promising advances made in cancer treatment in recent years. In non-small cell lung cancer (NSCLC), biomarkers predicting response to IC treatments are currently lacking. We have recently identified Immunoscore-IC, a powerful biomarker that predicts the efficiency of immune-checkpoint inhibitors (ICIs) in NSCLC patients. Immunoscore-IC is an in vitro diagnostic assay that quantifies densities of PD-L1+, CD8+ cells, and distances between CD8+ and PD-L1+ cells in the tumor microenvironment. Immunoscore-IC can classify responder vs non-responder NSCLC patients for ICIs therapy and is revealed as a promising predictive marker of response to anti-PD-1/PD-L1 immunotherapy in these patients. Immunoscore-IC has also shown a significant predictive value, superior to the currently used PD-L1 marker. In colorectal cancer (CRC), the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab improved progression-free survival (PFS) in patients with previously untreated metastatic CRC. In the AtezoTRIBE trial, Immunoscore-IC emerged as the first biomarker with robust predictive value in stratifying pMMR metastatic CRC patients who critically benefit from checkpoint inhibitors. Thus, Immunoscore-IC could be a universal biomarker to predict response to PD-1/PD-L1 checkpoint inhibitor immunotherapy across multiple cancer indications. Therefore, cancer patient stratification (by Immunoscore-IC), based on the presence of T lymphocytes and PD-L1 potentially provides support for clinicians to guide them through combination cancer treatment decisions.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2243169biomarkerscancerimmune checkpoint (IC)immunoscoreimmunotherapyPD-L1 |
| spellingShingle | Assia Hijazi Carlotta Antoniotti Chiara Cremolini Jérôme Galon Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response OncoImmunology biomarkers cancer immune checkpoint (IC) immunoscore immunotherapy PD-L1 |
| title | Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response |
| title_full | Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response |
| title_fullStr | Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response |
| title_full_unstemmed | Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response |
| title_short | Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response |
| title_sort | light on life immunoscore immune checkpoint a predictor of immunotherapy response |
| topic | biomarkers cancer immune checkpoint (IC) immunoscore immunotherapy PD-L1 |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2243169 |
| work_keys_str_mv | AT assiahijazi lightonlifeimmunoscoreimmunecheckpointapredictorofimmunotherapyresponse AT carlottaantoniotti lightonlifeimmunoscoreimmunecheckpointapredictorofimmunotherapyresponse AT chiaracremolini lightonlifeimmunoscoreimmunecheckpointapredictorofimmunotherapyresponse AT jeromegalon lightonlifeimmunoscoreimmunecheckpointapredictorofimmunotherapyresponse |